GUCY2C molecular staging personalizes colorectal cancer patient management.
Publication/Presentation Date
6-1-2012
Abstract
While the most significant prognostic and predictive marker in the management of colorectal cancer patients is cancer cells in regional lymph nodes, approximately 30% of patients whose lymph nodes are ostensibly free of tumor cells by histopathology ultimately develop recurrent disease reflecting occult metastases. Molecular techniques utilizing highly specific markers and ultra-sensitive detection technologies have emerged as powerful staging platforms to establish prognosis and predict responsiveness to chemotherapy in colorectal cancer patients. This review describes the evolution of the tumor suppressor GUCY2C as a prognostic and predictive molecular biomarker that quantifies occult tumor burden in regional lymph nodes for staging patients with colorectal cancer.
Volume
6
Issue
3
First Page
339
Last Page
348
ISSN
1752-0371
Published In/Presented At
Gong, J. P., Schulz, S., Hyslop, T., & Waldman, S. A. (2012). GUCY2C molecular staging personalizes colorectal cancer patient management. Biomarkers in medicine, 6(3), 339–348. https://doi.org/10.2217/bmm.12.24
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
22731908
Department(s)
Administration and Leadership
Document Type
Article